medigraphic.com

2018, Número 3

<< Anterior Siguiente >>

Rev Hematol Mex 2018; 19 (3)


El programa de trasplantes de la Clínica Ruiz de Puebla: a 25 años de su creación

Murrieta-Álvarez I, Olivares-Gazca JC, León-Peña A, Pérez-López R, Vallejo-Villalobos MF, Ruiz-Delgado GJ, Ruiz-Argüelles GJ

Idioma: Español
Referencias bibliográficas: 152
Paginas: 141-152
Archivo PDF: 346.27 Kb.


RESUMEN

El programa de trasplante de células hematopoyéticas de la Clínica Ruiz inició con el primer trasplante que se realizó en Puebla, en mayo de 1993. Desde entonces, y hasta diciembre de 2017, se han realizado 803 trasplantes en el centro. Estos procedimientos se han llevado a cabo mediante el uso de células alogénicas, autólogas y placentarias. Este programa privado es el más grande en México y se encuentra entre los primeros tres programas públicos y privados del país. En conjunto con el programa de trasplantes del Hospital Universitario de Nuevo León, se han hecho más de 150 publicaciones en revistas médicas indexadas nacionales e internacionales. Algunas de estas publicaciones han sido reconocidas por instituciones nacionales e internacionales como: la Agrupación Mexicana para el Estudio de la Hematología, la Academia Nacional de Medicina, la Fundación Mexicana para la Salud, el Instituto CARSO y el Center for International Bone Marrow Transplantation Research en Estados Unidos. El fundador de este programa recibió, junto con el Dr. David Gómez Almaguer, el Distinguished Service Award 2017, otorgado por el Center for International Bone Marrow Transplantation Research.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Alemán-Hoey DD, Arizpe-Bravo D, et al. Autotrasplante en leucemia aguda de células totipotenciales movilizadas con filgrastim. Rev Invest Clin Méx 1993;45:479-480.

  2. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B, Marín- López A, et al. Filgrastim mobilized peripheral blood stem cells can be stored at 4 degrees and used in autografts to rescue high-dose chemotherapy. Am J Hematol 1995;48:100-103.

  3. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B, Marín-López A, Delgado-Lamas JL. Non-cryopreserved peripheral blood stem cells autotransplants for hematological malignancies can be performed en rely on an outpatient basis. Am J Hema tol 1998;58:161-164.

  4. Ruiz-Argüelles GJ, Lobato-Mendizábal E, Ruiz-Argüelles A, Pérez-Romano B, et al. Non-cryopreserved unmanipulated hematopoietic peripheral blood stem cell autotransplant program: long term results. Arch Med Res 1999;30:380- 384.

  5. Ruiz-Argüelles GJ, Gómez-Rangel D, Ruiz-Delgado GJ, Ruiz- Argüelles A, et al. Results of an autologous non-cryopreserved, unmanipulated peripheral blood hematopoietic stem cell transplant program: A single institution, 10-year experience. Acta Haematol 2003;110:179-183.

  6. Vela-Ojeda J, García-Ruiz-Esparza MA, Padilla-González Y, Gómez-Almaguer D, et al. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan. Ann Hematol 2007;86:277-282.

  7. López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. ¿Es cierto que el trasplante de médula ósea autóloga mejora el pronóstico de los pacientes con mieloma múltiple?: Experiencia de una sola institución en México. Med Univ 2008;10:187-189.

  8. López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplant 2009;44;715-719.

  9. Reyes-Torres V, Hernández-Arizpe A, López-Otero A, Ruiz- Delgado G y col. El AMD3100 (plerixafor) puede mejorar la movilización de células hematopoyéticas para hacer trasplantes autólogos. Informe de un caso. Med Univ 2009;11:202-206.

  10. Ruiz-Delgado GJ, Ruiz-Argüelles GJ. El trasplante autólogo sigue siendo importante en el tratamiento del mieloma múltiple. Rev Hematol Méx 2011:12:1-2.

  11. Ruiz-Delgado GJ, Calderón-García J, Alarcón-Urdaneta C, Ruiz-Argüelles GJ. An increased body mass index is not an adverse prognostic factor in persons undergoing autologous hematopoietic stem cell transplantation. Medicina Univ 2011;13:122-126.

  12. Ruiz-Delgado GJ, Fernández-Macouzet M, Alarcón- Urdaneta C, Ruiz-Argüelles GJ. The role of post-autograft maintenance therapy in multiple myeloma: A propos d ́un cas. Rev Hematol Méx 2012:13:39-41.

  13. Ruiz-Argüelles GJ, Gómez-Almaguer D. El trasplante de médula ósea, el premio Nobel y la muerte del Dr. Edward Donnall Thomas. Rev Hematol Méx 2013;14:1-2.

  14. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Garcés-Eisele J. ¿Es necesario el trasplante de médula ósea en el tratamiento de la leucemia mieloiode aguda? Rev Hematol Méx 2013;14:1-4.

  15. Zamora-Ortiz G, Velázquez-Sánchez-de-Cima S, Hernández- Reyes J, Vargas-Espinosa J y col. Veinte años de experiencia con trasplante de células hematopoyéticas en la Clínica Ruiz de Puebla, México. Rev Hematol Méx 2013;14:63-70.

  16. Karduss-Urueta A, Ruiz-Argüelles GJ, Pérez R, Ruiz-Delgado GJ, et al. Cell-Freezing Devices Are not strictly needed to start an autologous hematopoietic transplantation program: non-cryopreserved peripheral blood stem cells can be used to restore hematopoiesis after high dose chemotherapy: a multicenter experience in 268 autografts in patients with multiple myeloma or lymphoma. Study on behalf of the Latin-American Bone Marrow Transplantation Group (LABMT). Blood 2014124:849.

  17. Ruiz-Argüelles GJ, Léón-Peña AA, León-González M, Vargas-Espinosa J, et al. Outpatient hematopoietic grafting in patients with multiple sclerosis employing autologous non-cryopreserved peripheral blood stem cells: a feasibility study. Br J Haema tol 2016;173:17.

  18. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, Piñeiro LA. Dos casos de trasplantes heterólogos con sangre periférica. Rev Invest Clin Méx 1997;49:41-45.

  19. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, et al. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transplant 2000;25:131-133.

  20. Ruiz-Argüelles GJ. Quimioterapia versus minitrasplante en el tratamiento de la leucemia aguda mieloblástica. Gac Méd Méx 2000;136:25-26.

  21. Gómez-Almaguer D, Ruiz-Argüelles GJ, González-Llano O, Ruiz-Argüelles A, Cantú-Rodríguez OG. Trasplante de células hematopoyéticas de sangre periférica utilizando quimioterapia inmunosupresora sin destrucción de la médula ósea: “Minitrasplante”. Resultados de un programa prospectivo y multicéntrico. Gac Méd Méx 2002;138:235-239.

  22. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, et al. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001;66:241-244.

  23. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Gómez-Almaguer D, López-Martinez B, et al. Features of the engraftment of allogeneic hematopoietic stem cells using reduced-intensity conditioning regimens. Leuk Lymphoma 2001;42:145-150.

  24. Ruiz-Argüelles GJ. Outpatient programs of myeloablative chemotherapy, autologous and allogeneic bone marrow transplantation. Haematologica 2000;85:1233-1234.

  25. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martinez B. Editorial: ¿Por qué se están haciendo los minitrasplantes de médula ósea? Rev Invest Clin Méx 2001;53:110-111.

  26. Ruiz-Argüelles GJ, Gómez-Almaguer D, Velázquez-Ferrari M, Ruiz-Delgado GJ, Ruiz-Argüelles A. Salvage non-myeloablative allogeneic hematopoietic stem cell transplantation in two adults with advanced stages of leukemia. Rev Hematol 2001;2:9-11.

  27. Ruiz-Argüelles GJ. Simplification, not demystification nor trivialization of stem cell transplantation. Haematologica 2001;86;07.

  28. Ruiz-Argüelles GJ. Foro Clínico: El efecto de injerto contra tumor en leucemia granulocítica crónica. Rev Invest Clín Mex 2002;54:154-160.

  29. Ruiz-Argüelles GJ, López-Martinez B, Santellán-Olea MR, Abreu-Díaz G, et al. Follow up of hematopoietic chimerism in individuals given allogeneic hematopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: A prospective study in a single institution. Leukemia Lymph 2002;43:1509-1511.

  30. Ruiz-Argüelles GJ. Resultados del protocolo mexicano (Monterrey-Puebla) para llevar a cabo trasplantes alogénicos no mieloablativos (TANM). Gac Méd Mex 2002;138:139-141.

  31. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002;87:894-896.

  32. Ruiz-Argüelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: Results of the Mexican approach. Int J Hematol 2002;76:376-379.

  33. Gómez-Almaguer D, Ruiz-Argüelles GJ, Tarín-Arzaga LC, González-Llano O, et al. Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience. Biol Blood Marrow Transpl 2003;9:157-161.

  34. Ruiz-Argüelles GJ, López-Martinez B, Gómez-Rangel D, Estrada E, et al. Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: A single institution experience. Hematology 2003;8:151-154.

  35. Ruiz-Argüelles GJ, López-Martinez B, López-Ariza B. Successful allogeneic stem cell transplantation with non-myeloablative conditioning in patients with relapsed Hodgkin’s disease following autologous stem cell transplantation. Arch Med Res 2003;34:242-245.

  36. Ruiz-Argüelles GJ. Trasplante alogénico no mieloablativo (TANM): La experiencia de Puebla y Monterrey. Gac Méd Méx 2003;139:151-154.

  37. Ruiz-Argüelles GJ. Actualidades en el trasplante de células progenitoras: Rompiendo dogmas. Gac Méd Méx 2003;139:154-156.

  38. Ruiz-Argüelles GJ, Gómez-Almaguer D. El efecto de injerto contra tumor en el tratamiento del cáncer. Hemos (Venezuela) 2002;3:9-11.

  39. Ruiz-Argüelles GJ. Non-myeloablative bone marrow transplantation. Arch Med Res 2003;34:554-557.

  40. Ruiz-Argüelles GJ, Gómez-Rangel JD, Ponce-de-León S, González-Déctor L, et al. The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease. Am J Hematol 2004;75;200-204.

  41. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Rangel JD, Vela-Ojeda J, et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allografting: A prospective study. Leuk Lymphoma 2004;45:1191-1195.

  42. Ruiz-Argüelles GJ, Bordes-Aznar J, Díaz-Caballero N, Ruiz- Delgado GJ. La importancia del quimerismo en medicina. Gac Méd Méx 2004;140:573-575.

  43. Ruiz-Argüelles GJ, Gómez-Almaguer D. Breaking dogmata to help patients: non-myeloablative hematopoietic stem cell transplantation. Expert Opin Biol Ther 2004;4:1693- 1699.

  44. Ruiz-Argüelles GJ, López-Martinez B, Manzano C, Gómez- Rangel JD, Lobato-Mendizábal E. Significance of one human leukocyte antigen mismatch on outcome of nonmyeloablative allogeneic stem cell transplantation from related donors using the Mexican schedule. Bone Marrow Transpl 2005;35:335-339.

  45. Ruiz-Argüelles GJ. Introducción e historia del trasplante de médula ósea en México. Rev Hematol 2004;5:80-85.

  46. Ruiz-Argüelles GJ, Morales-Toquero A, Gómez-Rangel JD, López-Martínez B. Trasplante de células hematopoyéticas alogénicas en niños y adolescentes empleando esquema de acondicionamiento no mieloablativo. Experiencia en una sola institución. Bol Med Hosp Inf Méx 2005;62:88-95.

  47. Gómez-Almaguer D, Vela-Ojeda J, Jaime-Pérez JC, Gutiérrez- Aguirre CH, et al. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fudarabine-based conditioning regimen: the Mexican experience. Am J Hematol 2006;81:157-161.

  48. Jaime-Pérez JC, Ruiz-Argüelles GJ, Gómez-Almaguer D. Haematopoietic stem cell transplantation to treat aplastic anemia. Expert Opin Biol Ther 2005;5:617-626.

  49. Ruiz-Argüelles GJ, Morales-Toquero A, López-Martinez B, Tarín-Arzaga LC, Manzano C. Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. Bone Marrow Transpl 2005;36:715-720.

  50. Ruiz-Argüelles GJ. The Mexican approach to conduct allogeneic stem cell transplantation: braking dogmata and facing the Matthew effect. Hematology 2005;10:154-160.

  51. Ruiz-Argüelles GJ. Historia del trasplante de médula ósea en México. Rev Biomed 2005;16:207-213.

  52. Ruiz-Argüelles GJ, Gómez-Almaguer D, Vela-Ojeda J, Morales-Toquero A, et al. Extramedullary leukemic relapses following hematopoietic stem cell transplantation with non-myeloablative conditioning. Int J Hematol 2005;82:262-265.

  53. Ruiz-Argüelles GJ, Gómez-Almaguer D, Morales-Toquero A, Gutiérrez-Aguirre CH, Vela-Ojeda J, García-Ruiz-Esparza MA, Manzano C, Karduss A, Sumoza A, de-Souza C, et al. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005;36:1043-1047.

  54. Ruiz-Argüelles GJ, Gómez-Almaguer D, Tarín-Arzaga LC, Morales-Toquero A, et al. Second allogeneic peripheral blood stem cell transplants with reduced-intensity conditioning. Rev Invest Clin Méx 2006;58:34-38.

  55. Ruiz-Argüelles GJ, Gómez-Almaguer D. Nephrotic syndrome after non-myeloablative stem cell transplantation. Br J Haematol 2006;132:801-802.

  56. Parra A, Ramírez-Peredo J, Hidalgo R, Morales-Toquero A, Velásquez-Ramírez G, Ruiz-Argüelles A, et al. Altered functional status of the hypothalamic dopaminergic tone in patients with chronic graft versus host disease after allogeneic hematopoietic stem cell transplantation: A pilot study. Biol Blood Marrow Transpl 2006;12:566-572.

  57. Ruiz-Argüelles GJ, Gómez-Almaguer D. Trasplante de células progenitoras hematopoyéticas en México. Acta Médica, Hospital Ángeles 2006;4:25-28.

  58. Ruiz-Argüelles GJ, Suárez-González L, Gómez-Almaguer D. El método mexicano para trasplante de células totipotenciales hematopoyéticas rompió dogmas y favoreció a muchos pacientes. Med Int Méx 2006;22:128-138.

  59. Ruiz-Argüelles GJ, Suárez-González L, Gómez-Almaguer D, Ruiz-Delgado GJ. El “método mexicano” para hacer trasplantes de células totipotenciales hematopoyéticas alogénicas. Médica Sur Méx 2005;12:203-211.

  60. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Garcés-Eisele J, Ruiz- Argüelles A, et al. Donor cell leukemia after non-myeloablative allogeneic stem cell transplantation: A single institution experience. Leuk Lymphoma 2006;47:1952-1955.

  61. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Garcés-Eisele J. Donor cell leukemia: a critical review. Leuk Lymphoma 2007;48:25-38.

  62. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Ruiz- Delgado GJ, Rosillo C, Camoriano JK. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelobrosis with myeloid metaplasia. Am J Hematol 2007;82:400-402.

  63. Ruiz-Argüelles GJ, Suárez-González L, Gómez-Almaguer D. El “método mexicano” para hacer trasplantes de células totipotenciales hematopoyéticas. Parte I. De Trasplantes 2007;12:19-22.

  64. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Delgado GJ, Tarín-Arzaga LC. Transient mixed chimerism after stem cell transplantation can induce durable complete remissions in chronic myelogenous leukemia. Leuk Lymphoma 2006;47:2590-2592.

  65. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Delgado GJ, Tarín- Arzaga LC. Ocho años de experiencia con el “método mexicano” en la realización de trasplantes de células hematopoyéticas alogénicas. Gac Méd Méx 2007;143:231-235.

  66. Gutiérrez-Aguirre CH, Cantú-Rodríguez OG, González-Llano O, Salazar-Riojas R, González-Martinez O, Jaime-Pérez JC, et al. Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology 2007;12:193-197.

  67. Ruiz-Delgado GJ, Vázquez-Garza E, Fernández-Lara D, Priesca-Marìn M, Jiménez-Pérez G. Arizpe-Bravo D, et al. The cutaneous damage in transfusion-associated graft versus host disease is related to the presence on donorderived lymphocytes in the skin. A case report. Haema 2007;10:170-173.

  68. Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, González- Llano O, Mancías-Guerra C, Jaime-Pérez JC, Tarín-Arzaga LC, et al. Outpatient allografting using non-myeloablative conditioning: the Mexican experience. Bone Marrow Transplant 2007;40:119-123.

  69. Gutiérrez-Aguirre CH, Gómez-Almaguer D, Cantú-Rodríguez OG, González-Llano O, et al. Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study. Bone Marrow Transplant 2007;40:535-539.

  70. Ruiz-Argüelles GJ, Suárez-González L, Gómez-Almaguer D. El “método mexicano” para hacer trasplantes de células totipotenciales hematopoyéticas. Parte II. DeTrasplantes 2007;13:19-21.

  71. Ruiz-Argüelles GJ, Gil-Beristain J, Magaña M, Ruiz-Delgado GJ. Alemtuzumab-induced resolution of refractory cutaneous chronic graft versus host disease. Biol Bone Marrow Transpl 2008;14:7-9.

  72. Ruiz-Argüelles GJ, Gómez-Almaguer D. Editorial: De profetas, santos (Mateo y Marcos) y trasplantes de médula ósea en niños. Bol Méd Hosp Inf Méx 2007;64:139-142.

  73. Gómez-Almaguer D, Ruiz-Argüelles GJ, Tarín-Arzaga LC, González-Llano O, Gutiérrez-Aguirre CH, Cantú-Rodriguez O, et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transpl 2008;14:10-15.

  74. Ruiz-Argüelles GJ, Tarín-Arzaga LC, González-Carrillo ML, Gutiérrez-Riveroll KI, et al. Therapeutic choices in patients with Ph1 (+) chronic myelogenous leukemia living in México in the tyrosine kinase inhibitors (TKI) era: stem cell transplantation or TKIs? Bone Marrow Transplant 2008;42:23-28.

  75. Ruiz-Argüelles GJ, Gómez-Almaguer D. Making allogeneic bone marrow transplantation available to patients in developing countries: The Mexican Experience. Open Hematol J 2008;2:30-36.

  76. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Moreno-Ford V. Alemtuzumab-induced resolution of pulmonary non-infectious complication in a patient with chronic graft versus host disease. Biol Bone Marrow Transpl 2008;14:1434- 1435.

  77. Ruiz-Argüelles GJ. Stem cell transplantation in developing countries. In Prayoonwiwat W, Rojnuckarin P (editors). Education Book. The XXXIInd World Congress of the International Society of Hematology. Thailand, Bangkok, 2008:233.

  78. Ruiz-Delgado GJ, Gutiérrez-Riveroll KI, Gutiérrez-Aguirre CH, Gómez-Almaguer D, Eyzaguirre-Zapata R, Priesca- Marín M, et al. A single apheresis procedure in the donor may be enough to complete an allograft using the “Mexican Method” of non-ablative allografting. Biol Bone Marrow Transpl 2008;15:113.

  79. Gutiérrez-Aguirre CH, Cantú-Rodríguez OG, González-Llano O, Jaime-Pérez JC, et al. Reduced-intensity allogeneic versus autologous peripheral blood stem cell transplantation in patients with Hodgkin’s and non-Hodgkin’s lymphoma. Biol Blood Marrow Transpl 2008;15:67.

  80. Ruiz-Delgado GJ, Gutiérrez-Riveroll KI, Gutiérrez-Aguirre CH, Gómez-Almaguer D, et al. A single apheresis procedure in the donor may be enough to complete an allograft using the “Mexican Method” of non-ablative allografting. Blood Transfus 2009;7:127-131.

  81. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Calderón-Meza E, Ruiz-Argüelles A, Garcés-Eisele J. Donor-derived hairy cell leukemia. Leuk Lymphoma 2009;50:1712-1714.

  82. Ruiz-Argüelles GJ, Ruiz-Delgado GJ. Enfermedad de injerto contra huésped. Rev Hematol Méx 2010;11:31-32.

  83. Gutiérrez-Aguirre CH, Ruiz-Argüelles G, Cantú-Rodríguez OG, González-Llano O, Jaime-Pérez JC, García-Rodríguez F, et al. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Ann Hematol 2010;10:1045-1052.

  84. Cantú OG, Gutiérrez H, Ruiz-Argüelles GJ, López A, Mancías C, Martinez S, et al. Incidence of graft versus host disease (GVHD) in patients with allogeneic peripheral hematopoietic stem cell transplantation after a non-myeloablative conditioning. Haematologica 2010;95:653.

  85. Ruiz-Delgado GJ, Rodríguez-Romo L, Tarín-Arzaga LC, Lutz- Presno J, et al. Reduced-intensity allografting in childhood acute lymphoblastic leukemia. Biol Bone Marrow Transplant 2011;17:439-440.

  86. Ruiz-Delgado GJ, Lutz-Presno JA, Alarcón-Urdaneta C, Calderón-García J, Ruiz-Argüelles GJ. Body mass index as an indicator of prognosis in patients undergoing allogeneic hematopoietic stem cell transplantation. Rev Hematol Méx 2011;12:28-31.

  87. Cantú-Rodriguez OG, Gutiérrez-Aguirre CH, Jaime-Pérez JC, Treviño-Montemayor OR, et al. Low incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral blood stem cell transplantation employing a reduced-intensity conditioning. Eur J Haematol 2011; 87;521-530.

  88. Parra A, Ramírez-Peredo J, Reyes E, Hidalgo R, Macías- Gallardo J, Lutz-Presno J, et al. Moderate hyperprolactinemia is associated with survival in patients with acute graft-versus- host disease after allogeneic stem cell transplantation. Hematology 2012;17:85-92.

  89. Ruiz-Argüelles GJ, Gómez-Almaguer D, Steensma DP. Outdated dogma? Busulfan, seizure prophylaxis and stem cell allografting. Am J Hematol 2012;87:941.

  90. Ruiz-Argüelles GJ, Gómez-Almaguer D. Editorial: Allografting on outpatient basis can decrease GVHD prevalence, severity. Hem Onc Today 2012;13:8.

  91. Ruiz-Delgado GJ, Lutz-Presno JA, Alarcón-Urdaneta C, Calderón-García J, Ruiz-Argüelles GJ. Body mass index as an indicator of prognosis in patients undergoing allogeneic hematopoietic stem cell transplantation: a single institution experience. Biol Blood Marrow Transplant 2013;19:211-232.

  92. Velázquez-Sánchez-de-Cima S, Zamora-Ortiz G, Hernández- Reyes J, Rosales-Durón AD, et al. Oral versus intravenous fudarabine as part of a reduced-intensity conditioning for allogeneic stem cell transplantation. Acta Haematol 2014;132:125-128.

  93. Zamora-Ortiz G, Velázquez-Sánchez-de-Cima S, Ponce-de- León S, Gutiérrez-Aguirre CH, et al. Secondary malignancies after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning and outpatient conduction. Hematology 2014;19:435-440.

  94. Zamora-Ortiz G, Velázquez-Sánchez-de-Cima S, Ponce-de- León S, Gutiérrez-Aguirre CH, et al. Subsequent malignant neoplasms after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning and outpatient conductions. Biol Blood Marrow Transplant 2014;20:249-250.

  95. González MP, Martagón NA, Hernández J, Gómez A, et al. Los pacientes sometidos a trasplantes de células hematopoyéticas alogénicas con esquema de intensidad reducida tienen un mejor componente mental en calidad de vida relacionada con la salud que un grupo control. Rev Hematol Mex 2014;15:195.

  96. Schcolnik-Cabrera A, Labastida-Mercado N, Galindo-Becerra LS, Gómez-Almaguer D, et al. Reduced-intensity stem cell allografting for PNH patients in the eculizumab era: the Mexican experience. Hematology 2015;20:263-266.

  97. Vázquez-Mellado A, Navarro-Cabrera JR, Abello-Polo V, Gutierrez-Aguirre CH, et al. Unmanipulated peripheral blood stem cells can be safely used to allograft patients with severe aplastic anemia: the impact of ATG in Latin American experience. Blood 2014,124;1255.

  98. González-Ramírez MP, Miravete-Lagunes K, Gómez-de- León A, Ponce-de-León S, Tenorio-Rojo AP, Martagón- Herrera NA, et al. Health-related quality of life in leukemia survivors of allogeneic hematopoietic stem cell transplantation employing the Mexican reduced-intensity conditioning. Rev Invest Clin Méx 2015:67:109-116.

  99. Ruiz-Argüelles GJ. The changing pattern of the admission to the intensive care unit of allografted patients. Acta Haematol 2016;135:70-71.

  100. León-González MG, León-Peña AA, Scholnick-Cabrera A, Labastida-Mercado N, et al. Trasplante de células hematopoyéticas alogénicas con esquema de acondicionamiento de intensidad reducida para pacientes con hemoglobinuria paroxística nocturna (HPN) en la era del eculizumab: La experiencia mexicana. Rev Hematol Méx 2015;16:233.

  101. González-Llano O, González-López EE, Ramírez-Cazares AC, Ruiz-Argüelles GJ, Gómez-Almaguer D. Outpatient haploidentical peripheral bood stem-cell trasplantation with post-transplant cyclophosphamide in children and adolescents. Blood 2015;126:4389.

  102. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, González-Lllano O, Gómez-Almaguer D. Haploidentical bone marrow transplantation in 2015 and beyond. Curr Oncol Rep 2015;17:57.

  103. Ruiz-Argüelles GJ, Gómez-Rangel D, Sánchez-Anzaldo J, Ruiz-Argüelles A y col. Trasplante de células de cordón umbilical: informe de dos casos. Medicina Univ 2002;4:233- 235.

  104. Ruiz-Argüelles GJ, Reyes-Núñez V, Garcés-Eisele J, Warwick RM, et al. Acquired hemoglobin S trait in an adult patient with secondary acute myelogenous leukemia allografted with matched unrelated umbilical cord blood cells using a non-ablative conditioning regimen. Haema 2005;8:492- 496.

  105. Ruiz-Argüelles GJ. Amoebic paralytic ileus in a patient given an autologous stem cell transplantation. Haema 2006;9:431-432.

  106. Mancías-Guerra C, Ruiz-Delgado GJ, Manzano C, Díaz- Hernández MA, et al. Umbilical cord blood transplantation using non-myeloablative conditioning: The Mexican experience. Hematology 2006;11:355-359.

  107. Ruiz-Delgado GJ, Mancías-Guerra C, González-Carrillo ML, Ojeda-López Y, et al. Trasplante alogénico de células hematopoyéticas de dos cordones umbilicales. Medicina Univ 2007;9:112-116.

  108. Ruiz-Delgado GJ, Mancías-Guerra C, Tamez-Gómez EL, Rodríguez-Romo LN, et al. Dimethylsulfoxide (DMSO) induced toxicity in cord blood stem cell transplantation: report of three cases and review of the literature. Acta Haematol 2009;122:1-5.

  109. Ruiz-Delgado GJ, Mancías-Guerra C, Macías-Gallardo J, González-Llano O, et al. Long term results of placental blood allografting using reduced-intensity conditioning: Multicenter experience in a developing country. Hematology 2011;16:155-159.

  110. Handgretinger R, Chen X, Pfeiffer M, Mueller I, et al. Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation. Ann NY Acad Sci 2007;1106:279-289.

  111. Muñoz-Maldonado GE, Salinas-Domínguez R, Gómez- Almaguer D, Guzmán-López S y col. Trasplante autólogo de células hematopoyéticas de médula ósea para el tratamiento de isquemia crítica en la insuficiencia arterial periférica en el paciente diabético. Informe preliminar. Medicina Univ 2008;10:29-35.

  112. Rodríguez-Romo L, González-Llano O, Mancías-Guerra C, Jaime-Pérez JC, et al. Pediatric hematopoietic SCT in Mexico: recent activity and main problems. Bone Marrow Transplant 2010;46:607-609.

  113. Ruiz-Delgado GJ, López-Otero A, Hernández-Arizpe A, Ramírez-Medina A, Ruiz-Argüelles GJ. Poor hematopoietic stem cell mobilizers in multiple myeloma: a single institution experience. Mediterr J Hematol Infect Dis 2010;2:2010016.

  114. Ruiz-Argüelles GJ, Cazares-Ordoñez Y, Ruiz-Delgado GJ. Algunas observaciones sobre el rezago en la práctica de los trasplantes hematopoyéticos en México. Rev Hematol Méx 2011;12:1-4.

  115. Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A Mexican way to cope with stem cell transplantation. Hematology 2012;17:195- 197.

  116. Galo-Hooker EG, Ruiz-Delgado GJ, Ruiz-Arguelles. In pursuit of the graft-versus-myeloma effect: A single institution experience. Biol Blood Marrow Transplant 2013;19:238.

  117. Velázquez-Sánchez-de-Cima S, Zamora-Ortiz G, Ruiz- Delgado GJ, Ruiz-Argüelles GJ. Breaking another dogma: Successful hematopoietic stem cell transplantation in patients over 60 years of age: a single institution’s, 20-year experience. Rev Hematol Méx 2013;14:3-8.

  118. González MP, Martagón NA, Hernández J, Zamora G, y col. El género como factor pronóstico de la supervivencia postrasplante de células hematopoyéticas totipotenciales: Experiencia en una sola institución. Rev Hematol Mex 2014;15:196.

  119. Sotomayor C, Seber A, Bonfim C, Bouzas L, Bujan W, Daudt L, et al. Formación en trasplante de células progenitoras hematopoyéticas en América Latina: Estado actual. Grupo Latinoamericano de Trasplante de Médula Ósea (LABMT). Rev Hematol Méx 2014;15:37-42.

  120. Galindo-Becerra S, Labastida-Mercado N, Rosales-Padrón J, García-Chávez J, et al. Outcome of recipients of hematopoietic stem cell transplants who require intensive care unit support: a single institution experience. Acta Haematol 2015;134:119-124.

  121. Ruiz-Argüelles GJ, Abello-Polo V, Arrais-Rodrígues C, Bouzas LF, et al. Publications of bone marrow transplants in Latin America. A report of the Latin American Group of Bone Marrow Transplantation. Bone Marrow Transplant 2015;50:1130-1131.

  122. Ruiz-Argüelles GJ. Stem cell transplantation procedures are becoming affordable for individuals living in developing (middle income) countries. Acta Haematol 2016:135:79-80.

  123. González-Llano O, González-López EE, Ramírez-Cázares AC, Marcos-Ramírez ER, et al. Haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide in children and adolescents with hematological malignancies. Pediatr Blood Cancer 2016. doi: 10.1002/pbc.26131.

  124. Ruiz-Argüelles GJ. The changing pattern of the admission to the intensive care unit of allografted patients. Acta Haematol 2016;135:70-71.

  125. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, González-Lllano O, Gómez-Almaguer D. Haploidentical bone marrow transplantation in 2015 and beyond. Curr Oncol Rep 2015;17:57. doi: 10.1007/s11912-015-0482-9.

  126. León-González M, León-Peña AA, Vallejo-Villalobos MF, Ruiz-Argüelles A, Ruiz-Argüelles GJ. Comparación de dos presentaciones de filgastrim en México empleadas para movilizar células hematopoyéticas totipotenciales de la médula ósea a la sangre periférica: Estudio prospectivo en una sola Institución. Rev Hematol Méx 2015;16:224.

  127. León-Peña AA, León-González MG, Galindo-Becerra LS, Labastida-Mercado N y col. La evolución de los pacientes trasplantados con células madre hematopoyéticas quienes recibieron estancia en una unidad de cuidados intensivos: experiencia de una sola institución. Rev Hematol Méx 2015;16:229.

  128. León-Peña AA, León-González MG, Ruiz-Argüelles GJ, Abello-Polo V y col. Las publicaciones de los autores latinoamericanos sobre trasplante de médula ósea. Un estudio del Grupo Latinoamericano de Trasplantes de Médula Ósea. Rev Hematol Méx 2015;16:230.

  129. León-González MG, León-Peña AA, Scholnick-Cabrera A, Labastida-Mercado N, et al. Trasplante de células hematopoyéticas alogénicas con esquema de acondicionamiento de intensidad reducida para pacientes con hemoglobinuria paroxística nocturna (HPN) en la era del eculizumab: la experiencia mexicana. Rev Hematol Méx 2015;16:233.

  130. González-Llano O, González-López EE, Ramírez-Cázares AC, Marcos-Ramírez ER y col. Trasplante de células hematopoyéticas de sangre periférica haploidéntico ambulatorio con ciclofosfamida postrasplante en niños y adolescentes. Rev Hematol Méx 2015;16:234.

  131. Ruiz-Argüelles GJ, Léón-Peña AA, León-González M, Vargas- Espinosa J, et al. Trasplante hematopoyético extrahospitalario en pacientes con esclerosis múltiple usando células madre autólogas de sangre periférica no congeladas: un estudio de factibilidad. Rev Hematol Méx 2015;16:234.

  132. González-Llano O, González-López EE, Ramírez-Cázares AC, Ruiz-Argüelles GJ, Gómez-Almaguer D. Outpatient haploidentical peripheral blood stem-cell trasplantation with post-transplant cyclophosphamide in children and adolescents. Blood 2015;126:4389.

  133. Martinez-Rolon J, Baldomero H, Jaimovich G, Rivas M, et al. Hematopoietic stem cell transplant activity in Latin America: Predominant increase in autologous and modest increase in allogeneic HCT with high use of unrelated cord blood grafts. Blood 2015;126:4492.

  134. González-Llano O, González-López EE, Ramírez-Cázares AC, Marcos-Ramírez ER, et al. Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide in children and adolescents with hematological malignancies. Pediatr Blood Cancer 2016.doi: 10.1002/pbc.26131.

  135. Gómez-Almaguer D, Cantú-Rodríguez OG, Gutiérrez- Aguirre CH, Ruiz-Argüelles GJ. The treatment of CML at an environment with limited resources. Hematology 2016:1-7.

  136. Ruiz-Delgado GJ, León Peña AA, Gómez-de-León A, Ruiz- Argüelles GJ. Clearance of donor cell leukemia by means of graft versus leukemia effect: A case report. Hematology 2016:1-4.

  137. Ruiz-Delgado GJ, Hernández-Reyes J, González-Ramírez MP, Martagón-Herrera NÁ, et al. Donor cell leukemia (DCL): A prospective study of its identification and treatment. Gac Méd Méx 2015;151:582-587.

  138. Ruiz-Argüelles GJ, León-Peña AA, León-González M, Vargas-Espinosa J, et al. Outpatient hematopoietic grafting in patients with multiple sclerosis employing autologous non-cryopreserved peripheral blood stem cells: A feasibility study. Br J Haematol 2016;173:17.

  139. Gómez-Almaguer D, Vázquez-Mellado A, Navarro-Cabrera JR, Abello-Polo V, Milovic V, García J, et al. The Latin American experience of allografting patients with severe aplastic anemia: real-world data on the impact of stem cell source and ATG administration in HLA-identical sibiling trasplants. Bone Marrow Transplant 2016;10.1038/ bmt.2016.212.

  140. Motolinia-Muloz Y, Gastélum-Cano JM, Tenorio-Páez C, Ruiz-Argüelles GJ. Hemophagocytic lymphohistiocytosis in a patient with myelomatous activity after autologous bone marrow transplant. Rev Hematol Mex 2017 July;18(3):139-145.

  141. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Garces-Eisele J, Perez- Romano B, Reyes-Nuñez V. Donor cell leukemia after nonmyeloablative allogeneic stem cell transplantation: a single institution experience. Leuk Lymphoma 2006;47(9):1952-5

  142. Weisdorf D, Ruiz-Argüelles GJ, Srivastava A, Gómez-Almaguer D, Szer J. Economic Challenges in Hematopoietic Cell Transplantation: How Will New and Established Programs Face the Growing Costs? Biol Blood Marrow Transplant 2017;23(11):1815:1816

  143. Ruiz-Argüelles GJ, León-Peña AA, León-González M, et al. A Feasibility Study of the Full Outpatient Conduction of Hematopoietic Transplants in Persons with Multiple Sclerosis Employing Autologous Non-Cryopreserved Peripheral Blood Stem Cells. Acta Haematol 2017;137(4):214-9.

  144. Jaimovich G. Latin America: the next region for haematopoietic transplant progress. Bone Marrow Transplant 2017;52(5):671-7.

  145. Jaimovich G, Martinez-Rolon J, Baldomero H, et al. The Latin American experience of allografting patients with severe aplastic anaemia: real-world data on the impact of stem cell source and ATG administration in HLA-identical sibling transplants. Bone Marrow Transplant 2017;52(1):41-6.

  146. León-González M, León-Peña AA, Vallejo-Villalobos MF, Núñez-Cortés AK, Ruiz-Argüelles GJ, Ruiz-Delgado GJ. Mexican biosimilar filgrastim for autologous hematopoietic stem cell mobilization and transplantation. Rev Invest Clin 2016;68(4):181-3.

  147. González-Llano O, González-López EE, Ramírez-Cázares AC, Marcos-Ramírez ER, Ruiz-Argüelles GJ, Gómez-Almaguer D. Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide in children and adolescents with hematological malignancies. Pediatr Blood Cancer 2016;63(11):2033-7.

  148. Karduss-Urueta A, Gale RP, Gutiérrez-Aguirre CH, Herrera- Rojas MA, Murrieta Álvarez I, Pérez-Fontalvo R, Ruiz-Delgado GJ, Ruiz-Rojas G, Jimovich G, Feldman L, Labastida-Mercado N, Endara A, Castro M, Galindo-Becerra S, Cardona-Molina MA, Gómez-Almaguer D, Ruiz-Argüelles GJ. Freezing the gra ft is not necessary for autotransplants for plasma cell myelomas and lymphoma. Bone Marrow Transplant; 2018 Jan 12; doi: 10.1038/s41409-017-0047-7. [Epub ahead of print]

  149. Ruiz-Argüelles GJ, Gómez-Almaguer D. Hematopoietic stem cell transplants for persons with multiple sclerosis: Is this the best therapeutic option? Medicina Universitaria. 2017. http://doi.org/10.1016/j.rmu.2017.10.003

  150. León-González M, Núñez-Cortés AK, León-Peña AA, Torres-Priego MS, Zulbarán-Y-Rojas A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. El programa de trasplantes de células hematopoyéticas de Clínica Ruiz de Puebla (1993-2016). Rev Hematol Mex 2016;17(3):205-213.

  151. Ruiz-Argüelles GJ, Olivares-Gazca JC, Murrieta-Álvarez I, Blumenkron-Marroquin D, González-López EE, Ruiz- Argüelles A. Modifications to the “classical” autologous hematopoietic stem cell transplantation in multiple sclerosis: efficacy and safety study of a less toxic approach which improves the neurological condition: a Mexican perspective. Blood 2017;130:3290.

  152. Martin PJ. Presentation of the 2017 Distinguished Service Awards by the CIBMTR, February 24, 2017. Rev Hematol Mex 2017 January;18(1):33-35.




2020     |     www.medigraphic.com